Dowling oration 1975. Fibrinolysis and vasculitis.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004727:Endothelium / Q000473:pathology; D005032:Ethylestrenol / Q000008:administration & dosage; D005260:Female; D005337:Fibrin / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D005500:Follow-Up Studies; D006651:Histocytochemistry; D006801:Humans; D007249:Inflammation / Q000097:blood; D007871:Leg Ulcer / Q000097:blood; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use; D011693:Purpura / Q000097:blood; D051381:Rats; D012871:Skin Diseases / Q000188:drug therapy / Q000503:physiopathology*; D013924:Thrombophlebitis / Q000097:blood; D014652:Vascular Diseases / Q000097:blood*; D014945:Wound Healing
D045930:Anabolic Agents; D005337:Fibrin; D005032:Ethylestrenol; D010629:Phenformin; D005341:Fibrinolysin